2017
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M. Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016. Journal Of Translational Medicine 2017, 15: 236. PMID: 29145885, PMCID: PMC5691855, DOI: 10.1186/s12967-017-1341-2.Peer-Reviewed Original ResearchConceptsT-cell therapyCombination therapyMetastatic melanomaChemokine receptorsT cellsHoming capacitySurvival rateTumor-Infiltrating Lymphocyte TherapyStage IV melanoma patientsAdoptive T-cell therapyCell therapyBRAF inhibitor monotherapyImmune checkpoint blockersSetting of treatmentIdentification of patientsChimeric antigen receptorEfficient combination therapyEmpowerment of patientsOptimize treatment regimensDifferent therapeutic agentsMelanoma BridgeImmunotherapy agentsOutcome enhancementCheckpoint blockadeCheckpoint blockers
2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. Journal Of Translational Medicine 2014, 12: 277. PMID: 25348889, PMCID: PMC4232645, DOI: 10.1186/s12967-014-0277-z.Peer-Reviewed Original ResearchConceptsProlong progression-free survivalOverall survivalMelanoma patientsMetastatic melanomaPathway inhibitorTumor microenvironmentImmune-modulating antibodiesLigand 1 pathwayMelanoma Bridge meetingProgression-free survivalMetastatic melanoma patientsCell death 1Adoptive cell transferNovel therapeutic targetContemporary clinical managementImportance of biomarkersFuture drug developmentMitogen-activated protein kinase pathway inhibitorsDifferent immunotherapiesImmune inhibitoryMelanoma BridgeDurable responsesSystemic therapyDeath-1Immune therapy